Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
10.99
+0.29 (2.71%)
At close: May 12, 2025, 4:00 PM
10.99
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Syndax Pharmaceuticals stock have an average target of 35.91, with a low estimate of 17 and a high estimate of 51. The average target predicts an increase of 226.75% from the current stock price of 10.99.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 7 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $16 → $17 | Hold | Maintains | $16 → $17 | +54.69% | May 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +191.17% | May 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $39 → $41 | Buy | Maintains | $39 → $41 | +273.07% | Mar 20, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $35 → $39 | Buy | Maintains | $35 → $39 | +254.87% | Mar 4, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $42 | Strong Buy | Maintains | $45 → $42 | +282.17% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
86.06M
from 23.68M
Increased by 263.44%
Revenue Next Year
197.46M
from 86.06M
Increased by 129.44%
EPS This Year
-3.94
from -3.72
EPS Next Year
-2.85
from -3.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 184.0M | 250.2M | 491.6M | ||
| Avg | 86.1M | 197.5M | 327.7M | ||
| Low | 56.2M | 128.9M | 224.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 677.0% | 190.7% | 149.0% | ||
| Avg | 263.4% | 129.4% | 66.0% | ||
| Low | 137.1% | 49.8% | 13.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.76 | -1.29 | -0.89 | ||
| Avg | -3.94 | -2.85 | -1.82 | ||
| Low | -4.56 | -3.49 | -2.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.